catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
Company profile
Ticker
CPRX
Exchange
Website
CEO
Patrick McEnany
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Catalyst Pharmaceutical Partners, Inc., CATALYST PHARMACEUTICAL PARTNERS, INC.
SEC CIK
Corporate docs
Subsidiaries
Catalyst Pharmaceuticals Ireland, Ltd. ...
CPRX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
8-K
Available in the U.S. by Prescription for Patients Aged Two Years and Older
13 Mar 24
8-K
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD
21 Feb 24
8-K
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock
9 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
5 Jan 24
424B5
Prospectus supplement for primary offering
5 Jan 24
Transcripts
CPRX
Earnings call transcript
2023 Q3
9 Nov 23
CPRX
Earnings call transcript
2023 Q2
10 Aug 23
CPRX
Earnings call transcript
2023 Q1
11 May 23
CPRX
Earnings call transcript
2022 Q4
16 Mar 23
CPRX
Earnings call transcript
2022 Q3
10 Nov 22
CPRX
Earnings call transcript
2022 Q2
10 Aug 22
CPRX
Earnings call transcript
2022 Q1
11 May 22
CPRX
Earnings call transcript
2021 Q4
17 Mar 22
CPRX
Earnings call transcript
2021 Q3
10 Nov 21
CPRX
Earnings call transcript
2021 Q2
10 Aug 21
Latest ownership filings
4
David S Tierney
10 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
4
Brian Elsbernd
28 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
4
Carmen Jeffrey Del
16 Feb 24
4
Richard J Daly
16 Feb 24
4
DONALD A DENKHAUS
16 Feb 24
4
David S Tierney
16 Feb 24
4
Charles B O'Keeffe
16 Feb 24
4
Steve Miller
16 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 120.97 mm | 120.97 mm | 120.97 mm | 120.97 mm | 120.97 mm | 120.97 mm |
Cash burn (monthly) | 19.27 mm | 11.26 mm | 12.67 mm | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 134.14 mm | 78.36 mm | 88.21 mm | n/a | n/a | n/a |
Cash remaining | -13.17 mm | 42.61 mm | 32.76 mm | n/a | n/a | n/a |
Runway (months of cash) | -0.7 | 3.8 | 2.6 | n/a | n/a | n/a |
Institutional ownership, Q3 2023
73.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 253 |
Opened positions | 37 |
Closed positions | 28 |
Increased positions | 77 |
Reduced positions | 86 |
13F shares | Current |
---|---|
Total value | 934.53 bn |
Total shares | 86.32 mm |
Total puts | 40.20 k |
Total calls | 42.80 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 15.38 mm | $179.83 bn |
Deerfield Management | 8.19 mm | $95.76 bn |
STT State Street | 7.57 mm | $88.50 bn |
Vanguard | 7.05 mm | $82.37 bn |
Flynn James E | 5.88 mm | $0.00 |
Dimensional Fund Advisors | 2.56 mm | $29.93 bn |
Geode Capital Management | 2.09 mm | $24.39 bn |
Royce & Associates | 1.61 mm | $18.84 bn |
NTRS Northern Trust | 1.44 mm | $16.80 bn |
Jacobs Levy Equity Management | 1.31 mm | $15.28 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | Tierney David S | Common stock, par value $0.001 per share | Sell | Dispose S | No | No | 15.68 | 25,000 | 392.00 k | 348,874 |
8 Apr 24 | Tierney David S | Common stock, par value $0.001 per share | Option exercise | Acquire M | No | No | 4.01 | 25,000 | 100.25 k | 373,874 |
8 Apr 24 | Tierney David S | Options to purchase common stock Common Stock | Option exercise | Acquire M | No | No | 4.01 | 25,000 | 100.25 k | 203,931 |
27 Mar 24 | Brian Elsbernd | Common stock, par value $0.001 per share | Sell | Dispose S | No | No | 16.44 | 25,000 | 411.00 k | 124,433 |
15 Feb 24 | Carmen Jeffrey Del | Common stock, par value $0.001 per share | Payment of exercise | Dispose F | No | No | 0 | 3,125 | 0.00 | 25,968 |
15 Feb 24 | Carmen Jeffrey Del | Common stock, par value $0.001 per share | Option exercise | Acquire M | No | No | 0 | 10,667 | 0.00 | 29,093 |
15 Feb 24 | Carmen Jeffrey Del | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 10,667 | 0.00 | 834,019 |
15 Feb 24 | Richard J Daly | Common stock, par value $0.001 per share | Payment of exercise | Dispose F | No | No | 0 | 1,186 | 0.00 | 212,147 |
15 Feb 24 | Richard J Daly | Common stock, par value $0.001 per share | Option exercise | Acquire M | No | No | 0 | 4,000 | 0.00 | 213,333 |
15 Feb 24 | Richard J Daly | RSU Common Stock | Grant | Dispose A | No | No | 0 | 4,000 | 0.00 | 1,771,012 |
News
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
27 Mar 24
Oppenheimer Reiterates Outperform on Catalyst Pharmaceuticals, Maintains $29 Price Target
27 Mar 24
Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $34 Price Target
22 Mar 24
Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $34 Price Target
14 Mar 24
Citigroup Initiates Coverage On Catalyst Pharmaceuticals with Buy Rating, Announces Price Target of $27
14 Mar 24
Press releases
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
25 Apr 24
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
28 Mar 24
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
27 Mar 24
Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?
21 Mar 24
Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
14 Mar 24